{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:26:19Z","timestamp":1768001179736,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ijrobp.2018.07.191","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T02:53:14Z","timestamp":1532573594000},"page":"1430-1437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial"],"prefix":"10.1016","volume":"102","author":[{"given":"Kyle","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent L.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton A.","family":"Medbery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly J.","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj V.","family":"Peddada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald B.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2018.07.191_bib1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2490-13-49","article-title":"A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy","volume":"13","author":"Bolzicco","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","article-title":"Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes","volume":"107","author":"Loblaw","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2013.53.8652","article-title":"Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: Comparison of toxicity","volume":"32","author":"Yu","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib7","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cncr.30101","article-title":"Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer","volume":"122","author":"Halpern","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jama.2017.1704","article-title":"Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years","volume":"317","author":"Barocas","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib11","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.ijrobp.2009.03.078","article-title":"Radiation dose-volume effects in radiation-induced rectal injury","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 3","key":"10.1016\/j.ijrobp.2018.07.191_bib12","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib13","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib14","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/cncr.30034","article-title":"Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012","volume":"122","author":"Baker","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib16","first-page":"113","article-title":"Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications","volume":"137","author":"Blasko","year":"1991","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(05)65970-8","article-title":"Long-term treatment related complications of brachytherapy for early prostate cancer: A survey of patients previously treated","volume":"166","author":"Talcott","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.radonc.2017.03.006","article-title":"Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?","volume":"123","author":"Helou","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2014.00301","article-title":"Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.radonc.2016.08.012","article-title":"Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy","volume":"121","author":"Qi","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib21","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.prro.2015.02.001","article-title":"Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Seymour","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13014-014-0241-3","article-title":"Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (>\/=50 cm(3))","volume":"9","author":"Janowski","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","article-title":"Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer","volume":"89","author":"Kim","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ijrobp.2015.12.010","article-title":"Predictive parameters of symptomatic hematochezia following 5-fraction gantry-based SABR in prostate cancer","volume":"94","author":"Musunuru","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2014.06.009","article-title":"Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy","volume":"112","author":"Elias","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.prro.2015.01.006","article-title":"Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Gomez","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/0284186X.2015.1037011","article-title":"Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer","volume":"55","author":"Kole","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.prro.2017.08.004","article-title":"A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life","volume":"8","author":"Jackson","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fonc.2014.00336","article-title":"A phase II study of stereotactic body radiation therapy for low-intermediate-high-risk prostate cancer using helical tomotherapy: Dose-volumetric parameters predicting early toxicity","volume":"4","author":"Macias","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2018.07.191_bib31","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/cncr.30519","article-title":"Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer","volume":"123","author":"Dess","year":"2017","journal-title":"Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618316444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618316444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T22:38:32Z","timestamp":1542235112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301618316444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0360301618316444"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.191","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}